Anticoagulation in patients with heart failure and normal sinus rhythm

American Journal of Health-System Pharmacy

Volumn 66, Issue 2, 2009, Pages 134-141

  Ripley, Toni L ^a   Nutescu, Edith ^b  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Anticoagulants; Heart failure; Hemorrhage; Mortality; Thromboembolism; Toxicity; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANGIOTENSIN ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA THROMBOGLOBULIN; CLOPIDOGREL; D DIMER; FIBRINOPEPTIDE A; HYDRALAZINE; IBOPAMINE; MILRINONE; NITRATE; THROMBIN ANTITHROMBIN COMPLEX; THROMBOCYTE FACTOR 4; VON WILLEBRAND FACTOR; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; CLINICAL TRIAL; CONSENSUS; HUMAN; HYPERCOAGULABILITY; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SINUS RHYTHM; SYSTOLIC HEART FAILURE; THROMBOEMBOLISM; THROMBOSIS;

EID: 58449098381     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080047     Document Type: Review

References (42)

1. Rosamond W, Flegal K, Furie K et al. Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008; 117:e25-146.
2. Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2005; 112:e154-235.
3. Heart Failure Society of America. Executive Summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2006; 12:10-38.
4. Becker RC, Meade TW, Berger PB et al. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008; 133(6, suppl):776S-814S.
5. Lip GY, Gibbs CR. Does heart failure confer a hypercoagulable state? Virchow's triad revisited. J Am Coll Cardiol. 1999; 33:1424-6.
6. Jafri SM, Ozawa T, Mammen E et al. Platelet function, thrombin and fibrinolytic activity in patients with heart failure. Eur Heart J. 1993; 14:205-12.
7. Jafri SM, Mammen EF, Masura J et al. Effects of warfarin on markers of hypercoagulability in patients with heart failure. Am Heart J. 1997; 134:27-36.
8. Fuster V, Gersh BJ, Giuliani ER et al. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol. 1981; 47:525-31.
9. Kyrle PA, Korninger C, Gössinger H et al. Prevention of arterial and pulmonary embolism by oral anticoagulants in patients with dilated cardiomyopathy. Thromb Haemost. 1985; 54:521-3.
10. Cioffi G, Pozzoli M, Forni G et al. Systemic thromboembolism in chronic heart failure: a prospective study in 406 patients. Eur Heart J. 1996; 17:1381-9.
11. Katz SD, Marantz PR, Biasucci L et al. Low incidence of stroke in ambulatory patients with heart failure: a prospective study. Am Heart J. 1993; 126:141-6.
12. Dunkman WB, Johnson GR, Carson PE et al. Incidence of thromboembolic events in congestive heart failure. Circulation. 1993; 87(6, suppl):VI94-101.
13. Loh E, Sutton MS, Wun CC et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med. 1997; 336:251-7.
14. Dries DL, Rosenberg YD, Waclawiw MA et al. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. J Am Coll Cardiol. 1997; 29:1074-80.
15. Siachos T, Vanbakel A, Feldman DS et al. Silent strokes in patients with heart failure. J Card Fail. 2005; 11:485-9.
16. Hays AG, Sacco RL, Rundek T et al. Left ventricular systolic dysfunction and the risk of ischemic stroke in a multiethnic population. Stroke. 2006; 37:1715-9.
17. Freudenberger RS, Hellkamp AS, Halperin IL et al. Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation. 2007; 115:2637-41.
18. Anderson GM, Jull E. The effect of dicumarol upon the mortality and incidence of thromboembolic complications in congestive heart failure. Am Heart J. 1950; 39:697-702.
19. Griffith GC, Stragnell R, Levinson DC et al. A study of the beneficial effects of anticoagulant therapy in congestive heart failure. Ann Intern Med. 1952; 37:867-87.
20. Harvey WP, Finch CA. Dicumarol prophylaxis of thromboembolic disease in congestive heart failure. N Engl J Med. 1950; 242:208-11.
21. 21. Echemann M, Alla F, Briancon S et al. Antithrombotic therapy is associated with better survival in patients with severe heart failure and left ventricular systolic dysfunction (EPICAL study). Eur J Heart Fail. 2002; 4:647-54.
22. Falk RH, Pollak A, Randon PK et al., for the PROMISE investigators. The effect of warfarin on prevalence of stroke in patients with severe heart failure. J Am Coll Cardiol. 1993; 21:218A. Abstract.
23. De Boer RA, Hillege HL, Tjeerdsma G et al. Both antiplatelet and anticoagulant therapy may favorably affect outcome in patients with advanced heart failure. A retrospective analysis of the PRIME-II trial. Thromb Res. 2005; 116:279-85.
24. Al-Khadra AS, Salem DN, Rand WM et al. Warfarin anticoagulation and survival: a cohort analysis from the studies of left ventricular dysfunction. J Am Coll Cardiol. 1998; 31:749-53.
25. Cleland JG, Findlay I, Jafri S et al. The Warfarin/Aspirin Study in Heart Failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J. 2004; 148:157-64.
26. Massie BM, Krol WF, Ammon SE et al. The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. J Card Fail. 2004; 10:101-12.
27. Massie BM. WATCH results: American College of Cardiology Annual Scientific Session 2004. www.medscape.com/viewarticle/471782 (accessed 2008 Jan 27).
28. Cokkinos DV, Haralabopoulos GC, Kostis JB et al. Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. Eur J Heart Fail. 2006; 8:428-32.
29. Pullicino P, Thompson JL, Barton B et al. Warfarin versus aspirin in patients with reduced cardiac ejection fraction (WARCEF): rationale, objectives, and design. J Card Fail. 2006; 12:39-46.
30. Internet Stroke Center at Washington University. Stroke Trials Registry. www.strokecenter.org/Trials/TrialDetail.aspx?tid=83 (accessed 2008 Nov 17).
31. Schulman S, Beyth RJ, Kearon C et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008; 133(6, suppl):257S-2598S.
32. Reisner EH, Norman J, Field WW et al. The effect of liver dysfunction on the response to dicumarol. Am J Med Sci. 1949; 217:445-7.
33. Stats D, Davison S. The increased risk of hypoprothrombinemic effect of a small dose of dicumarol in congestive heart failure. Am J Med Sci. 1949; 218:318-23.
34. Visser LE, Bleumink GS, Trienekens PH et al. The risk of over-anticoagulation in patients with heart failure on coumarin anticoagulants. Br J Haematol. 2004; 127:85-9.
35. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five controlled trials. Arch Intern Med. 1994; 154:1449-57. [Erratum, Arch Intern Med. 1994; 154:2254.]
36. Pengo V, Legnani C, Noventa F et al. Oral anticoagulant therapy in patients with non-rheumatic atrial fibrillation and risk of bleeding. A multicenter inception cohort study. Thromb Haemost. 2001; 85:418-22.
37. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998; 105:91-9.
38. Adams KF Jr, Fonarow GC, Emerman CL et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005; 149:209-16.
39. Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003; 362:759-66.
40. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001; 345:1667-75.
41. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure. Lancet. 1999; 353:2001-7.
42. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997; 336:525-33.